Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Larimar Therapeutics Inc. buy melinda

Start price
€54.88
07.02.19 / 50%
Target price
€97.42
13.02.19
Performance (%)
-11.83%
End price
€48.38
13.02.19
Summary
This prediction ended on 13.02.19 with a price of €48.38. The price of Larimar Therapeutics Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -11.83%. melinda has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Larimar Therapeutics Inc. 2.344% 2.344% 53.037% -54.828%
iShares Core DAX® -1.670% -1.001% 10.864% 12.563%
iShares Nasdaq 100 -4.184% -1.145% 37.458% 41.078%
iShares Nikkei 225® -4.967% -5.783% 18.828% 0.655%
iShares S&P 500 -2.834% -0.572% 25.875% 39.960%

According to melinda what are the pros and cons of Larimar Therapeutics Inc. for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Cons

Comments by melinda for this prediction

In the thread Zafgen Inc. diskutieren
Prediction Buy
Perf. (%) -11.83%
Target price 8.118
Change
Ends at 13.02.19

Biotechnologie und medizinische SecteurRecherche


Beruf
Logo Zafgen IncFonctionne als biopharmazeutisches Unternehmen

Zafgen, Inc. ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Anti-Adipositas-Behandlung in Eingriff ist, die den normalen Stoffwechsel von Fett und Regulationswege wieder her.

Sein Produkt: Beloranib, die in der klinischen Entwicklung der Phase 2 zur Behandlung von Fettleibigkeit und Überernährung in Prader-Willi-Syndrom ist, oder Fettleibigkeit mit Kraniopharyngeoms verbunden.

Das Unternehmen wurde am 22. November 2005 gegründet und ist in Boston, MA ansässig.

Anzahl der Mitarbeiter: 32 Personen.

Prediction Buy
Perf. (%) -11.83%
Target price 8.118
Change
Ends at 13.02.19

(Vom Mitglied beendet)

Stopped prediction by melinda for Larimar Therapeutics Inc.

buy
Larimar Therapeutics Inc.

Start price
Target price
Perf. (%)
€8.94
10.12.19
€13.00
04.11.21
20.81%
05.11.21

Could be worthwhile Investment >10% per year
buy
Larimar Therapeutics Inc.

Start price
Target price
Perf. (%)
€87.46
08.03.18
€97.42
25.06.18
16.58%
25.06.18

Could be worthwhile Investment >10% per year
buy
Larimar Therapeutics Inc.

Start price
Target price
Perf. (%)
€44.92
13.05.17
€54.12
14.11.17
-12.05%
14.11.17

Could be worthwhile Investment >10% per year
buy
Larimar Therapeutics Inc.

Start price
Target price
Perf. (%)
€78.15
07.04.16
€184.01
21.07.16
-54.46%
21.07.16

Could be worthwhile Investment >10% per year
buy
Larimar Therapeutics Inc.

Start price
Target price
Perf. (%)
€64.73
14.03.16
€81.18
04.04.16
26.76%
04.04.16

Could be worthwhile Investment >10% per year